Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx (Nasdaq: IFRX) closed an underwritten offering of 75,000,000 ordinary shares at $2.00 per share on May 8, 2026, raising aggregate gross proceeds of $150.0 million before underwriting discount and offering expenses. The company said net proceeds will fund pipeline activities, working capital and general corporate purposes.
InflaRx (Nasdaq: IFRX) priced an underwritten offering of 75,000,000 ordinary shares at $2.00 per share, for gross proceeds of approximately $150 million. The offering is expected to close on May 7, 2026, subject to customary closing conditions.
The company intends to use net proceeds to advance its pipeline activities and for working capital and general corporate purposes. Institutional participation includes several new and existing investors; Guggenheim Securities is lead bookrunner.
InflaRx (Nasdaq: IFRX) will develop izicopan in ANCA-associated vasculitis (AAV) and pursue rapid proof of concept in select life-threatening renal diseases (aHUS, IgAN, C3G).
The company is planning Phase 2 activity in AAV, open-label renal studies with data expected next year, a PK bridging study in China this year, and a Capital Markets Day in summer 2026. InflaRx estimates funding for planned programs and operations through 2029.
InflaRx (Nasdaq: IFRX) reported preclinical in vitro data showing low reactive metabolite formation for izicopan in human liver microsomes versus higher levels for avacopan. Differences exceeded 100-fold at 5–10 minutes and were ~10-fold at 20–40 minutes. InflaRx noted izicopan did not inhibit CYP3A4 in vitro and cited prior Phase 1 and Phase 2a safety and PK/PD data, including ≥90% blockade of C5a-induced neutrophil activation.
InflaRx cautioned that in vitro findings do not directly predict clinical outcomes but said the results support izicopan’s differentiated preclinical profile within the C5aR1 inhibitor class.
InflaRx (Nasdaq: IFRX) will release its first quarter 2026 financial and operating results on May 7, 2026 before the market opens. No conference call is planned. The company develops anti-inflammatory therapeutics including oral izicopan and intravenous vilobelimab, and has operations in Germany and the U.S.
InflaRx (Nasdaq: IFRX) reported it has regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1). The closing bid price was at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and Nasdaq closed the matter.
The company reiterated its lead programs, izicopan and vilobelimab, and listed investor contacts and subsidiaries.
InflaRx (Nasdaq: IFRX) reported mechanistic in vitro data showing izicopan does not exhibit time-dependent inhibition of CYP3A4 up to 100 µM, supporting a low risk of clinically relevant drug–drug interactions (DDIs) and liver toxicity. The Ki/Kinact study used midazolam and testosterone probes and confirmed prior marginal IC₅₀ findings.
Company data also note favorable PK/PD (≥90% C5a blockade over 14 days), tolerability in single doses 3–240 mg and multiple doses up to 90 mg twice daily, and supportive Phase 2a efficacy signals in hidradenitis suppurativa and chronic spontaneous urticaria.
InflaRx (Nasdaq: IFRX) will participate in the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026. The company will hold one-on-one investor meetings and present its pipeline highlights, including izicopan and vilobelimab, and corporate overview.
Contact details for investor relations and media are provided.
InflaRx (Nasdaq: IFRX) presented Phase 3 vilobelimab data for pyoderma gangrenosum at the 2026 AAD Annual Meeting (March 27-31, 2026). The trial enrolled 54 patients and was stopped early for futility. Results showed higher complete remission and ulcer-closure rates, strong C5a suppression (-76.6% vs -13.5%), and a generally favorable safety profile.
The company plans FDA discussions on a PG development path and expects future PG work likely with a partner.
InflaRx (Nasdaq: IFRX) reported full‑year 2025 results and highlighted positive Phase 2a data for oral C5aR inhibitor izicopan, prioritizing hidradenitis suppurativa (HS) and discussing Phase 2b design with the FDA. Cash and marketable securities totaled €46.2 million, funding operations to mid‑2027.
Company plans a China PK bridging study, ongoing collaborator discussions, and a virtual Capital Markets Day this spring.